Wells Fargo maintains Underperform on Valeant Pharmaceuticals (NYSE: VRX).The analyst called revenues "weak" and noted "the variance ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE